namenda ocd | Augmentation With Memantine in Obsessive-Compulsive Diso

Keyword	CPC	PCC	Volume	Score	Length of keyword
namenda ocd	0.43	0.4	6021	40	11
namenda	0.11	0.9	435	20	7
ocd	1.01	0.1	6208	71	3

Keyword	CPC	PCC	Volume	Score
namenda ocd	0.54	0.5	1407	51

Search Results related to namenda ocd on Search Engine

Augmentation With Memantine in Obsessive-Compulsive Disorder
nih.gov

https://pubmed.ncbi.nlm.nih.gov/31846244/

WEBDec 3, 2019 · PMID: 31846244. DOI: 10.4088/JCP.19f13163. Abstract. Patients with obsessive-compulsive disorder (OCD) who do not respond adequately to serotonin reuptake inhibitor (SRI) therapy and cognitive behavioral therapy commonly receive SRI augmentation in the form of an atypical antipsychotic drug.

DA: 36 PA: 90 MOZ Rank: 61

Memantine for Treatment-Resistant OCD | American Journal of …
psychiatryonline.org

https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.162.11.2191-a

WEBNov 1, 2005 · Add-on memantine was well tolerated and resulted in clinically significant reduction of OCD symptom severity. Prior treatment resistance and the proximity between symptomatic improvement and the initiation of memantine point to its possible attenuating effect on the symptoms of OCD.

DA: 64 PA: 1 MOZ Rank: 69

A systematic review and meta-analysis: Memantine augmentation …
nih.gov

https://pubmed.ncbi.nlm.nih.gov/31630042/

WEBMemantine. A considerable proportion of obsessive-compulsive disorder (OCD) patients receiving first-line pharmacological therapy, fail to fully respond to treatment and continue to exhibit significant symptoms. In this systematic review, we evaluate the efficacy of memantine, as a glutamate-modulating agent, ….

DA: 37 PA: 87 MOZ Rank: 91

An open-label trial of memantine in treatment-resistant obsessive
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085808/

WEBMemantine may be beneficial for treatment-resistant OCD as an augmenting agent. Keywords: Glutamatergic modulation, memantine, obsessive compulsive disorder. Recent literature strongly implicate disrupted neurotransmission of glutamate within the cortico-striato-thalamocortical circuitry in the pathogenesis of obsessive-compulsive disorder …

DA: 77 PA: 53 MOZ Rank: 65

Treatment-Resistant OCD: Strategies and Novel Treatment Options
psychiatrictimes.com

https://www.psychiatrictimes.com/view/treatment-resistant-ocd-strategies-and-novel-treatment-options

WEBJan 24, 2022 · SPECIAL REPORT: TREATMENT RESISTANCE. Obsessive-compulsive disorder (OCD) is characterized by repetitive thoughts, urges, and images (obsessions) and/or repetitive behaviors or mental acts aimed at reducing anxiety or distress (compulsions). OCD is thought to have a lifetime prevalence of between 1% to 3% and is a significant …

DA: 18 PA: 61 MOZ Rank: 92

Memantine augmentation of sertraline in the treatment of …
biomedcentral.com

https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-021-03642-z

WEBJan 12, 2022 · OCD is characterized by recurrent, unwanted and intrusive thoughts, urges or images which causes anxiety and discomfort, and/or by repetitive behaviors or mental acts that tries to prevent or reduce the associated anxiety [ 3, 4 ]. If left untreated, the course is generally chronic [ 5 ].

DA: 13 PA: 72 MOZ Rank: 38

Glutamate modulators in the treatment of obsessive-compulsive disorder
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517847/

WEBSeveral lines of neurochemical and genetic evidence suggests that glutamate dysregulation may contribute to OCD, although much remains unclear. The off-label use of a number of pharmacological agents approved for other indications has been investigated in …

DA: 71 PA: 28 MOZ Rank: 90

Treatment-resistant OCD: Pharmacotherapies in adults
sciencedirect.com

https://www.sciencedirect.com/science/article/pii/S0010440X2200058X

WEBJan 1, 2023 · Serotonin reuptake inhibitor (SRI) medications are well established as first-line pharmacotherapeutic treatment for Obsessive-Compulsive Disorder (OCD). However, despite the excellent safety profile and demonstrated efficacy of these medications, a substantial proportion of individuals with OCD fail to attain sufficient benefit from SRIs.

DA: 12 PA: 88 MOZ Rank: 27

Augmentation With Memantine in Obsessive-Compulsive Disorder
psychiatrist.com

https://www.psychiatrist.com/jcp/augmentation-with-memantine-in-ocd/

WEBPublished: December 3, 2019. ABSTRACT. Patients with obsessive-compulsive disorder (OCD) who do not respond adequately to serotonin reuptake inhibitor (SRI) therapy and cognitive behavioral therapy commonly receive SRI augmentation in the form of an atypical antipsychotic drug. Memantine is another augmentation strategy that has been trialed.

DA: 20 PA: 99 MOZ Rank: 44

A systematic review and meta-analysis: Memantine
sciencedirect.com

https://www.sciencedirect.com/science/article/abs/pii/S0165178119317810

WEBDec 1, 2019 · Obsessive-compulsive disorder (OCD) is a common and debilitating neuropsychiatric disorder worldwide and is characterized by recurrent obsessions and compulsions that cause marked distress to the afflicted individuals (Rabe-Jablonska and Bienkiewicz, 1994).

DA: 54 PA: 95 MOZ Rank: 50